The board of directors of Uni-Bio Science Group Limited announced that after the trading hours of The Stock Exchange of Hong Kong Limited on 4 January 2019, clinical data as contained in the bioequivalence study ("BE Study") on Acarbose tablets jointly developed by Beijing Genetech Pharmaceutical Co., Limited (a wholly-owned subsidiary of the Company) and Beijing Baiao Pharmaceutical Co. Ltd. has been formally accepted by China Food and Drug Administration with reference number of CYHS1900008(Guo) (CYHS1900008) and CYHS1900007(Guo) (CYHS1900007), corresponding to the oral tablets under two specifications of 50mg and 100mg for this submission respectively. This submission, if approved, means that the Company will be qualified for batch production of such product, which will be produced and launched to the Mainland China market as newly approved generic drugs. Acarbose tablet is an oral anti-diabetic drug which belongs to the Alpha-Glucosidase Inhibitors class. It is used to treat Type 2 diabetes and is reimbursed under the National Reimbursement Drug List. It targets patients with pre-diabetes condition who need to be treated in early stage, and those with post prandial hyperglycemia under control. Acarbose tablet, with a market value as high as USD 3.2 billion, is effective for Asian people with a carbohydrate-rich diet. As a small-molecule drug for Type 2 diabetes, Acarbose tablet has limited competitors in China. Thus far, the Group has completed the BE Study on Acarbose tablets, and remains optimistic about the BE findings. To the knowledge of the Board, the Group is taking the lead on the research progress among other ongoing projects of the same category and it is expected that the Group could be in the first batch of manufacturers to apply for the production approvals, which is expected to be officially granted in the first half of 2019. In view of the fact that the progress of developing Acarbose tablets is three months ahead of the original schedule, the Board remains optimistic about the official introduction of this product within 2019. In the meantime, the Company is also actively exploring long-term collaboration with raw material suppliers on Acarbose tablets and other generic drug production to improve cost control and secure a stable supply of active pharmaceutical ingredients.